Tesamorelin vs Ipamorelin
An FDA-approved GHRH analog that selectively trims visceral fat. A selective GH secretagogue that mimics ghrelin at GHS-R. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Tesamorelin | Ipamorelin | |
|---|---|---|
| Also known as | Egrifta | — |
| Type | Analog | Analog |
| Evidence | Clinical | Preclinical |
| Family | Growth & repair | Growth & repair |
| Class | Stabilized GHRH(1-44) analog | Synthetic pentapeptide GH secretagogue (GHRP) |
| Receptor | GHRH receptor (GHRHR), a class B GPCR | Growth hormone secretagogue receptor (GHS-R1a) |
| Molecular weight | ≈5,136 Da | ~711.9 Da |
| Half-life | ||
| Based on | Growth-hormone-releasing hormone | Ghrelin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Tesamorelin and Ipamorelin?
- Tesamorelin is an engineered analog based on Growth-hormone-releasing hormone; Ipamorelin is an engineered analog based on Ghrelin. Tesamorelin signals at GHRH receptor (GHRHR), a class B GPCR; Ipamorelin signals at Growth hormone secretagogue receptor (GHS-R1a).
- How do the half-lives of Tesamorelin and Ipamorelin compare?
- The reported circulating half-life of Tesamorelin is ~26-38 min (subcutaneous); Ipamorelin is ~2 h. These are reference values for the native or representative form — educational only, not dosing advice.
- Is Tesamorelin the same as Egrifta?
- Egrifta is a brand name of Tesamorelin. This comparison describes the molecules, not branded products.
Prefer the other order? Ipamorelin vs Tesamorelin. Or open the interactive comparison tool to add more molecules.